Kailera Therapeutics
KLRA · NASDAQ
$12.89+$1.46 (+12.77%)TodayMarket closed ·
Prev close $11.43
Who owns KLRA
Largest institutional holders, from their latest 13F filings
The 10 largest institutions hold 75.2% of KLRA’s shares.
- Bain Capital Private Equity, LP20.3%
- Bain Capital Life Sciences Investors, LLC17.4%
- Jiangsu Hengrui Pharmaceuticals Co. Ltd.8.9%
- RTW Investments L.P.8.3%
- Next 6 largest institutions20.3%
- All other shareholders24.8%
| Holder | Shares | % of shares |
|---|---|---|
| Bain Capital Private Equity, LP | 26.26M | 20.26% |
| Bain Capital Life Sciences Investors, LLC | 22.58M | 17.43% |
| Jiangsu Hengrui Pharmaceuticals Co. Ltd. | 11.51M | 8.88% |
| RTW Investments L.P. | 10.78M | 8.32% |
| CPP Investments | 7.30M | 5.64% |
| Atlas Venture | 5.17M | 3.99% |
| Fidelity Management & Research Company LLC | 3.89M | 3.00% |
| T. Rowe Price Associates, Inc. | 3.48M | 2.69% |
| Citadel Advisors LLC | 3.24M | 2.50% |
| Adage Capital Management, L.P. | 3.21M | 2.48% |
Largest mutual fund holders
| Holder | Shares | % of shares |
|---|---|---|
| Vanguard Health Care Fund | 2.19M | 1.69% |
| Vanguard Total Stock Market Index Fund | 1.18M | 0.91% |
| iShares Russell 2000 ETF | 1.17M | 0.90% |
| T. Rowe Price Health Sciences Fund | 904.28K | 0.70% |
| Vanguard Small-Cap Index Fund | 852.28K | 0.66% |
Insider trades
Form 4 filings by officers, directors and large holders
Insiders made no open-market buys or sales of KLRA in the last 6 months.
| Insider | Type | Shares | Value |
|---|---|---|---|
| Nicholson Nur | Award | 220.00K | — |
| Tregoning Kathleen | Award | 175.00K | — |
| Renaud Ronald C JR | Option exercise | 38.09K | — |
| Renaud Ronald C JR | Option exercise | 38.09K | $199.99K |
Short interest
Settled Sep 30, 2026
- Shares short
- 8.68M
- Days to cover
- 5.62
- % of shares outstanding
- 6.70%
- Average daily volume
- 1.55M
- Change since last report
- +45.6%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.